TabsDetailsBasic DetailsDate: Sunday, August 25, 2019Type: PresentationMedical Product: sodium-glucose cotransporter-2 (SGLT-2) inhibitorHealth Outcome(s): diabetic ketoacidosisMaterials: Analysis of SGLT2 Inhibitor Use in Patients with Type-1 Diabetes Mellitus and Rates of Diabetic KetoacidosisAdditional InformationInformationHost: 35th International Conference on Pharmacoepidemiology & Therapeutic Risk ManagementRelated Assessment(s): Abstracts of the 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Pennsylvania Convention Center, Philadelphia, PA, USA, August 24‐28, 2019Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic KetoacidosisSGLT-2 Inhibitor Use and Incidence of Diabetic Ketoacidosis in Patients with Type 1 Diabetes MellitusContributorsPresenter(s): Christian Hampp
